What are the indications, dosing regimen, contraindications, and monitoring requirements for finerenone in adults with chronic kidney disease and type 2 diabetes?

Finerenone: Indications, Dosing, Contraindications, and Monitoring

Finerenone is indicated for adults with type 2 diabetes and chronic kidney disease who have eGFR >25 ml/min per 1.73 m², normal serum potassium (≤4.8 mmol/L), and albuminuria >30 mg/g despite maximum tolerated RAS inhibitor therapy. 1

Clinical Context and Patient Selection

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, should be reserved for high-risk patients with persistent albuminuria despite standard-of-care therapy (RAS inhibitors and ideally SGLT2 inhibitors). 1, 2 The 2024 KDIGO guidelines position finerenone as add-on therapy rather than first-line treatment, recognizing that SGLT2 inhibitors have larger effects on both kidney and cardiovascular outcomes. 2

Key eligibility criteria:

• Type 2 diabetes with CKD
• eGFR >25 ml/min per 1.73 m²
• Albuminuria >30 mg/g (>3 mg/mmol)
• Already on maximum tolerated RAS inhibitor
• Baseline potassium ≤4.8 mmol/L

Dosing Regimen

Initial dosing is strictly determined by eGFR and potassium levels: 1

Starting Dose Algorithm:

• eGFR 25-59 ml/min per 1.73 m²: Start 10 mg once daily
• eGFR ≥60 ml/min per 1.73 m²: Start 20 mg once daily
• Potassium must be ≤4.8 mmol/L to initiate therapy

Dose Titration:

After 4 weeks, if potassium remains ≤4.8 mmol/L, increase from 10 mg to 20 mg daily in patients who started on the lower dose. 1

Important Dosing Considerations:

• Can be taken with or without food 3
• No dose adjustment needed for moderate renal or hepatic impairment per se, as starting dose already accounts for eGFR 3
• Contraindicated with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) 3
• Avoid concurrent strong or moderate CYP3A4 inducers 3

Contraindications

Absolute contraindications:

• Potassium >4.8 mmol/L at baseline
• eGFR ≤25 ml/min per 1.73 m²
• Concomitant strong CYP3A4 inhibitors 3

Relative contraindications requiring caution:

• Concurrent moderate CYP3A4 inhibitors (requires closer potassium monitoring)
• History of severe hyperkalemia

Monitoring Requirements

Potassium Monitoring Protocol (Critical):

The following algorithm is mandatory to prevent hyperkalemia: 1

Potassium Level	Action
≤4.8 mmol/L	• Continue current dose • Monitor K+ at 1 month, then every 4 months • Consider dose increase if on 10 mg
4.9-5.5 mmol/L	• Continue current dose • Monitor K+ every 4 months • Do NOT increase dose
>5.5 mmol/L	• HOLD finerenone immediately • Adjust diet/medications to lower K+ • Recheck K+ • Restart at 10 mg daily only when K+ ≤5.0 mmol/L

Monitoring Schedule:

1. Before initiation: Check potassium and eGFR
2. At 1 month: Check potassium (critical timing)
3. Every 4 months thereafter: Check potassium
4. With any dose change: Check potassium at 1 month
5. With CYP3A4 inhibitor initiation: Increase potassium monitoring frequency 3

Treatment Sequencing and Combination Therapy

The recommended treatment sequence for T2D with CKD is: 2

1. First: RAS inhibitor (ACE inhibitor or ARB)
2. Second: SGLT2 inhibitor (prioritized over finerenone due to larger effect size)
3. Third: Finerenone (if albuminuria persists despite above therapies)

Finerenone may be added to both RAS inhibitor AND SGLT2 inhibitor for patients with persistent high-risk albuminuria. 1 Recent evidence from the CONFIDENCE trial demonstrates that simultaneous initiation of finerenone with empagliflozin is safe and produces greater albuminuria reduction than either agent alone, though this is not yet standard practice. 4

Common Pitfalls and Practical Considerations

Critical pitfalls to avoid:

1. Starting finerenone before SGLT2 inhibitor: SGLT2 inhibitors should generally be prioritized first due to superior outcomes data 2

2. Inadequate potassium monitoring: The 1-month potassium check is non-negotiable—this is when hyperkalemia risk peaks 1

3. Discontinuing unnecessarily: If potassium rises to 4.9-5.5 mmol/L, continue therapy with monitoring rather than stopping 1

4. Ignoring drug interactions: Always screen for CYP3A4 inhibitors/inducers before prescribing 3

5. Using in patients without albuminuria: Finerenone is specifically for patients with persistent albuminuria >30 mg/g 1

Hyperkalemia management strategies:

• Dietary potassium restriction
• Adjust concomitant medications (reduce/stop potassium-sparing diuretics, NSAIDs)
• Consider potassium binders if needed to maintain therapy
• Do NOT immediately discontinue RAS inhibitors—manage potassium medically first 1

Evidence Strength

The recommendation for finerenone is graded 2A by KDIGO 2024, indicating moderate-strength evidence supporting its use in appropriately selected patients. 1 The FIDELIO-DKD and FIGARO-DKD trials demonstrated significant reductions in kidney and cardiovascular outcomes, with the FIDELITY pooled analysis confirming benefits across diverse CKD populations. 5 However, finerenone remains secondary to SGLT2 inhibitors in treatment hierarchy based on comparative effect sizes. 2